Wedge Industrial (000534) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
9 Jul, 2026Executive summary
Revenue for Q3 2025 reached ¥315.17 million, up 14.79% year-over-year; year-to-date revenue was ¥940.60 million, up 21.00% year-over-year.
Net profit attributable to shareholders for Q3 was ¥50.53 million, up 23.90% year-over-year; year-to-date net profit was ¥169.94 million, up 22.45% year-over-year.
Excluding non-recurring items, net profit for Q3 was ¥46.37 million, up 38.15% year-over-year; year-to-date was ¥156.66 million, up 31.79% year-over-year.
Financial highlights
Basic EPS for Q3 was ¥0.1005, up 20.94% year-over-year; year-to-date was ¥0.3402, up 21.24%.
Diluted EPS for Q3 was ¥0.0985, up 23.28% year-over-year; year-to-date was ¥0.3352, up 23.19%.
Gross margin improved as revenue growth outpaced cost increases, despite a 38.09% rise in operating costs due to strong high-temperature alloy sales.
Net cash flow from operating activities for Q3 was ¥16.64 million, down 67.45% year-over-year.
Total assets at period end were ¥4.35 billion, up 9.60% from the previous year-end.
Outlook and guidance
Significant increase in contract liabilities (up 625.89% from year start) signals robust order inflow and strong future revenue visibility.
Latest events from Wedge Industrial
- Net profit rose 12.49% YoY on higher revenue and robust pharmaceutical segment growth.000534
Q2 20249 Jul 2026 - Q3 2024 saw double-digit profit growth, robust cash flow, and major investments in expansion.000534
Q3 20249 Jul 2026 - Audit confirms accurate related party fund flows and significant intra-group transactions in 2024.000534
Q4 20249 Jul 2026 - Revenue and profit surged, with robust growth in pharma and alloy businesses and strategic investments.000534
Q2 20259 Jul 2026 - Revenue and net profit rose over 10% year-over-year, with robust growth in high-temperature alloys.000534
Q1 20259 Jul 2026 - Revenue up 19.62% to ¥1.29B, net profit up 2.22%, with strong R&D and no cash dividend.000534
Q4 20259 Jul 2026 - Q1 2026 saw revenue and profit growth, negative cash flow, and major strategic investment in a subsidiary.000534
Q1 20269 Jul 2026